Johnson & Johnson is joining forces with Sanofi for the commercialization of a potential first-in-class vaccine against extraintestinal pathogenic E. coli (ExPEC), which is currently in Phase III testing. The companies announced an agreement on 3 October in which Sanofi will pay J&J $175m up front plus development and commercial milestone fees in exchange for commercial rights to the vaccine.
J&J And Sanofi Team Up On Phase III E. Coli Vaccine
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
More from Deals
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.